e-learning
resources
Virtual 2020
Pre-Congress Content
Monoclonal antibodies; randomised controlled trials and real-world studies in asthma
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Omalizumab is an effective intervention in severe asthma with aspergillus sensitisation.
P. Wark (NewcastleNew Lambton Heights (NSW)Newcastle, Australia), S. Hussaini (NNewcastleew Lambton Heights (NSW), Australia), C. Holdar (NewcastleNew Lambton Heights (NSW), Australia), H. Powell (NewcastleNewcastleNew Lambton Heights (NSW), Australia), C. Oldmeadow (NewcastleNewcastleNewcastleNew Lambton Heights (NSW), Australia), P. Gibson (NewcastleNewcastleNewcastleNew Lambton Heights (NSW), Australia)
Source:
Virtual Congress 2020 – Monoclonal antibodies; randomised controlled trials and real-world studies in asthma
Session:
Monoclonal antibodies; randomised controlled trials and real-world studies in asthma
Session type:
E-poster session
Number:
2263
Disease area:
Airway diseases
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
P. Wark (NewcastleNew Lambton Heights (NSW)Newcastle, Australia), S. Hussaini (NNewcastleew Lambton Heights (NSW), Australia), C. Holdar (NewcastleNew Lambton Heights (NSW), Australia), H. Powell (NewcastleNewcastleNew Lambton Heights (NSW), Australia), C. Oldmeadow (NewcastleNewcastleNewcastleNew Lambton Heights (NSW), Australia), P. Gibson (NewcastleNewcastleNewcastleNew Lambton Heights (NSW), Australia). Omalizumab is an effective intervention in severe asthma with aspergillus sensitisation.. 2263
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Late Breaking Abstract - Implications of treatable traits and treatment choices on exacerbation risk in moderate-severe asthma
Management of Severe Asthma in Pediatric Patients by an Interdisciplinary Team in a Public Hospital Setting.
Impact of Dexamethasone on pathogen profile of COVID-19 patients requiring intensive care: a multicentre retrospective study
Related content which might interest you:
Omalizumab, a novel therapy for severe allergic asthma
Source: Eur Respir J 2001; 18: Suppl. 33, 37s
Year: 2001
Omalizumab in children with severe persistent allergic asthma
Source: Annual Congress 2010 - Managing asthma and allergic disease in children
Year: 2010
Omalizumab treatment reduces asthma exacerbations in children with moderate or severe persistent asthma
Source: International Congress 2017 – Paediatric asthma: treatment modalities and behavioural issues
Year: 2017
Omalizumab is effective in patients with severe persistent allergic asthma in a real-life setting irrespective of age
Source: Annual Congress 2009 - Towards improving asthma control
Year: 2009
Anti-IgE treatment: An alternative for severe allergic occupational asthma
Source: Annual Congress 2012 - Asthma and COPD at work: what are the effects of exposure and risk factors?
Year: 2012
Omalizumab provides long-term control in patients with moderate-to-severe allergic asthma
Source: Eur Respir J 2002; 20: 73-78
Year: 2002
Immunotherapy in severe asthma
Source: ERS webinar 2021: Immunotherapy in severe asthma
Year: 2021
Omalizumab therapy reduces asthma exacerbations in children with severe allergic (IgE-mediated) asthma irrespective of lung function at baseline
Source: Annual Congress 2009 - Difficult asthma in children: diagnostic and therapeutic challenges
Year: 2009
Real-life long-term omalizumab therapy in children with severe allergic asthma
Source: Eur Respir J 2015; 46: 856-859
Year: 2015
Assesment of long-term omalizumab treatment in severe allergic asthma
Source: Annual Congress 2012 - Asthma: risk factors and effect of anti-IgE
Year: 2012
Endotypes of severe allergic asthma patients who clinically benefit from Anti-IgE therapy
Source: International Congress 2018 – Studying novel biomarkers in asthma and COPD
Year: 2018
Omalizumab decreases IgE production in patients with severe allergic asthma
Source: Annual Congress 2012 - Aspects of clinical asthma
Year: 2012
Omalizumab is equally effective in persistent allergic oral corticosteroid-dependent asthma whether due to seasonal allergens or to perennial allergens
Source: International Congress 2015 – Asthma and lung immunology
Year: 2015
10 Year evaluation of patients with severe uncontrolled allergic asthma treated with Omalizumab.
Source: International Congress 2018 – Physiological and biological insights in asthma
Year: 2018
Omalizumab (Xolair®) reduces exacerbations in patients with moderate-to-severe persistent allergic asthma independent of former smoking status
Source: Annual Congress 2008 - Improving asthma and anti-allergic therapy
Year: 2008
Omalizumab therapy reduces oral corticosteroid use in patients with severe allergic (IgE-mediated) asthma: European real-life experience
Source: Annual Congress 2009 - Severe asthma and its treatment
Year: 2009
Persistency of treatment response to omalizumab in patients with severe allergic (IgE-mediated) asthma
Source: Annual Congress 2009 - Severe asthma and its treatment
Year: 2009
Omalizumab in severe adult atopic dermatitis associated to mild asthma treated with omalizumab
Source: Annual Congress 2012 - Asthma: assessment and treatment
Year: 2012
Anti-IgE therapy with omalizumab decreases exacerbations in patients with poorly controlled moderate-to-severe allergic asthma
Source: Eur Respir J 2003; 22: Suppl. 45, 203s
Year: 2003
Anti-IgE: lessons from clinical trials in patients with severe allergic asthma symptomatic despite optimised therapy
Source: Eur Respir Rev 2007; 16: 73-77
Year: 2007
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept